| *Sponsored
(Nasdaq: OKYO) Has Our Full Attention After Lucid Capital Markets' Analyst Tags $13 Target
August 1st Greetings Readers,
OKYO Pharma Limited (Nasdaq: OKYO) has taken over the top spot on our watchlist Friday.
On key reason why is an analyst report that came out yesterday.
In it, Lucid Capital Markets put out a target on OKYO of $13.
From yesterday's closing valuation, that target provides OKYO with over 350% potential upside.
Then there's OKYO's bullish technicals. Barchart is currently reporting 10+ as triggered across the short, medium, and long term.
Riding the announcement of positive top-line data just a couple weeks back, OKYO continues to fly under-the-radar.
For how much longer? That's the question.
Read the entire (Nasdaq: OKYO) report below and consider this profile for your watchlist. -----
Here's an interesting one...
With potential catalysts flying left and right around this under-the-radar profile, it has quickly pushed its way to the top of my watchlist.
Multiple analyst targets (at least 3) pointing to triple-digit potential upside?
Check.
A multitude of bullish technical indicators across the short, medium, and long term?
How about 11 triggered right now?
Major news announcements in the recent term suggesting Wall Street's attention may soon become extremely focused?
You got to see them to believe them!
Mix in a relatively low float which could lead to significantly heightened volatility potential and there's no doubt why this Nasdaq breakout idea has my immediate attention:
OKYO Pharma Limited (Nasdaq: OKYO)
OKYO Pharma Ltd. is a biopharmaceutical company dedicated to developing an innovative treatment for neuropathic corneal pain and dry eye disease.
The company aims to provide targeted therapy that not only alleviates pain but also controls inflammation, while enhancing ocular residence time for more effective, lasting relief.
And based on 5 potential breakout catalysts, (Nasdaq: OKYO) has risen to the top spot on my watchlist this Friday. Check them out:
(Nasdaq: OKYO) Recap - 5 Potential Breakout Catalysts Lead The Way!
No. 1 - At Least 3 Analyst Targets Are Suggesting OKYO To Have Triple-Digit Upside Potential!
No. 2 - A Multitude Of Bullish Technical Indicators Surround OKYO Across 3 Separate Terms.
No. 3 - Positive Top-Line Data Announced From Phase 2 Clinical Trial Results For Urcosimod.
No. 4 - A New Milestone For The Company Is Reached With FDA Granted Fast Track Designation To Urcosimod.
No. 5 - With A Relatively Low Float, Volatility Potential Could Be Heightened (Daily).
But more on those in a second...
Company Breakdown - Key Details About OKYO Pharma Limited (Nasdaq: OKYO)
Urcosimod (formerly called OK-101) Drug Candidate
Urcosimod is a novel class of chemerin (ChemR23 or CMKLR1) receptor agonist that produces an anti-inflammatory and reduction in neuropathic pain.
The chemerin receptor is a G protein-coupled receptor (GPCR) found on select immune, epithelial, and dorsal root ganglion/spinal cord neuronal cells.
Activation of chemerin receptor has been shown to modulate the resolution of inflammation and neuropathic pain.
Urcosimod can potentially benefit patients suffering from ocular pain and ocular inflammation.
Neuropathic Corneal Pain (NCP)
A chronic pain condition due to nerve damage or dysfunction in the corneal region. Severe eye pain, burning, foreign body sensation and light sensitivity (photophobia).
Can result from trauma, surgery (e.g., refractive surgery), infections, or conditions like dry eye disease that affect corneal nerves.
The pain is due to abnormal signaling in the corneal nerves, which may become sensitized or dysfunctional, leading to persistent pain.
No FDA approved treatment.
OKYO is the first company to receive an investigational new drug (IND) application clearance by the FDA to clinically evaluate a drug specifically to treat NCP.
Dry Eye
Dry Eye affects over 35% of the population aged 50+, with women representing approximately two-thirds of those affected.
Worldwide, ~700Mn patients suffer from dry eye disease.
Several side effects and modest efficacy of currently available drugs demand new therapies to treat dry eye disease.
Huge potential for new drugs for a $5Bn dry eye market.
Pipeline
OKYO is focused on developing innovative GPCR-based therapies for eye diseases with significant unmet needs with a market with substantial growth potential.
Specifically, the company is advancing first-in-class drug candidates aimed at treating ocular pain, dry eye disease, and uveitis.
OKYO’s lead drug candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. | 
No comments:
Post a Comment